Biocartis Strengthens Management Team with General Counsel Life Sciences and Biotechnology
LAUSANNE, Switzerland and MECHELEN, Belgium, January 15, 2013 /PRNewswire/ --
Biocartis, a molecular diagnostics company developing and commercializing innovative, high quality, easy to use platforms and clinically relevant oncology assays, announced today that Inge Basteleurs has joined the company as General Counsel. Inge will be a member of Biocartis' Executive Committee and a director of Biocartis NV.
Inge Basteleurs brings to Biocartis an impressive track record from a 17-year career as a senior international executive within the biotechnology and pharmaceutical industries.
She joins Biocartis from UCB NV, where she was Vice President Legal and Secretary General to the Board. Since 2006, Inge has held various functions at UCB NV and was ultimately appointed Vice President Legal, responsible for managing the company's business development, research and international markets' legal department. In this capacity, she was instrumental in completing several major financing transactions, bond issuances, M&A and licensing deals, totaling over 5.6bn Euro. Prior to joining UCB, Inge worked 7 seven years at Bayer BioScience NV, where her role included global legal responsibility for and membership of the management committee of several of Bayer BioScience's business areas, including commercial transactions, M&A, intellectual property licensing and government affairs. Inge started her career as an M&A/finance solicitor at Linklaters (De Bandt).
Inge received her Master in Law from KULeuven (Belgium), her LL.M from University College London (UK) and her additional degree in Managerial Economics from KULeuven.
"Inge brings to Biocartis a wealth of experience and a global perspective on a broad range of legal matters in the life sciences industry, together with her drive and fun personality which are consistent with Biocartis' culture and values. She will support Biocartis' transition to a global commercial enterprise. We are all excited for her contribution," commented Greg Parekh, Chief Executive Officer of Biocartis.
Commenting on her new role, Inge said: "Biocartis has all the potential to become a global leader in the transformation from traditional medicine toward personalized medicine and point of care diagnostics. I am delighted to be joining Biocartis, its strong Executive team and its consortium partners, at this exciting time, to help guide the launch of its highly innovative molecular diagnostics systems."
SOURCE Biocartis NV